Guggenheim Has Lowered Expectations for Regeneron Pharmaceuticals (NASDAQ:REGN) Stock Price

Regeneron Pharmaceuticals (NASDAQ:REGN) had its price target decreased by equities researchers at Guggenheim from $940.00 to $810.00 in a report issued on Thursday,Benzinga reports. The brokerage presently has a “buy” rating on the biopharmaceutical company’s stock. Guggenheim’s price objective points to a potential upside of 33.75% from the company’s previous close.

A number of other equities research analysts have also weighed in on the stock. The Goldman Sachs Group dropped their price objective on shares of Regeneron Pharmaceuticals from $917.00 to $804.00 and set a “buy” rating on the stock in a report on Wednesday. Robert W. Baird cut their price objective on Regeneron Pharmaceuticals from $759.00 to $652.00 and set a “neutral” rating on the stock in a report on Friday, April 25th. Bank of America decreased their target price on Regeneron Pharmaceuticals from $575.00 to $547.00 and set an “underperform” rating for the company in a report on Thursday, April 17th. BMO Capital Markets cut their price target on shares of Regeneron Pharmaceuticals from $865.00 to $800.00 and set an “outperform” rating on the stock in a report on Wednesday. Finally, Royal Bank of Canada dropped their price objective on shares of Regeneron Pharmaceuticals from $1,051.00 to $943.00 and set an “outperform” rating on the stock in a report on Wednesday. One investment analyst has rated the stock with a sell rating, five have issued a hold rating, eighteen have assigned a buy rating and three have assigned a strong buy rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $892.60.

Regeneron Pharmaceuticals Trading Up 2.6 %

NASDAQ:REGN opened at $605.61 on Thursday. The stock has a market capitalization of $66.21 billion, a price-to-earnings ratio of 15.82, a PEG ratio of 2.34 and a beta of 0.44. Regeneron Pharmaceuticals has a 52 week low of $525.99 and a 52 week high of $1,211.20. The company has a quick ratio of 3.95, a current ratio of 4.73 and a debt-to-equity ratio of 0.09. The firm has a 50 day moving average of $626.49 and a 200 day moving average of $711.45.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported $8.22 earnings per share (EPS) for the quarter, missing the consensus estimate of $8.83 by ($0.61). The company had revenue of $3.03 billion for the quarter, compared to analyst estimates of $3.40 billion. Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. The business’s revenue was down 3.7% compared to the same quarter last year. During the same quarter last year, the company earned $9.55 EPS. As a group, sell-side analysts anticipate that Regeneron Pharmaceuticals will post 35.92 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Regeneron Pharmaceuticals

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Pinney & Scofield Inc. acquired a new position in shares of Regeneron Pharmaceuticals during the 4th quarter valued at about $25,000. E Fund Management Hong Kong Co. Ltd. boosted its holdings in Regeneron Pharmaceuticals by 344.4% in the 1st quarter. E Fund Management Hong Kong Co. Ltd. now owns 40 shares of the biopharmaceutical company’s stock valued at $25,000 after purchasing an additional 31 shares during the last quarter. OFI Invest Asset Management purchased a new stake in shares of Regeneron Pharmaceuticals in the 4th quarter valued at approximately $28,000. Rakuten Securities Inc. increased its holdings in shares of Regeneron Pharmaceuticals by 62.5% during the 4th quarter. Rakuten Securities Inc. now owns 39 shares of the biopharmaceutical company’s stock worth $28,000 after buying an additional 15 shares during the last quarter. Finally, Tompkins Financial Corp purchased a new stake in shares of Regeneron Pharmaceuticals during the 1st quarter valued at approximately $32,000. Institutional investors and hedge funds own 83.31% of the company’s stock.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.